Poxel S.A. (POXEL.PA)
Develops drugs targeting mitochondrial dysfunction to treat diabetes and liver diseases.
0.20-0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-64.3%
The outlook
Poxel is trading near its 52-week low at €0.20, well below both its 50- and 200-day moving averages, signaling a weak trend. Analyst coverage appears thin, and the stock sits at just 2% of the way up its annual range. Current data shows a decidedly bearish lean.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Market cap
$12.4M
52-wk high
0.57
52-wk low
0.19
50-day avg
0.21
200-day avg
0.25
Trailing P/E
—